ID

26894

Beschreibung

Tamoxifen Citrate in Patients With Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00963209

Link

https://clinicaltrials.gov/show/NCT00963209

Stichworte

  1. 28.10.17 28.10.17 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

28. Oktober 2017

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Breast Cancer NCT00963209

Eligibility Breast Cancer NCT00963209

Criteria
Beschreibung

Criteria

diagnosis of breast cancer
Beschreibung

Breast Carcinoma

Datentyp

boolean

Alias
UMLS CUI [1]
C0678222
hormone-sensitive breast cancer defined as > 10% estrogen receptor and/or > 10% progesterone receptor positivity by immunohistochemistry
Beschreibung

Breast Carcinoma Hormone Responsive | Estrogen receptor positive Percentage Immunohistochemistry | Progesterone receptor positive Percentage Immunohistochemistry

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0678222
UMLS CUI [1,2]
C1512498
UMLS CUI [2,1]
C0279754
UMLS CUI [2,2]
C0439165
UMLS CUI [2,3]
C0021044
UMLS CUI [3,1]
C0279759
UMLS CUI [3,2]
C0439165
UMLS CUI [3,3]
C0021044
receiving treatment with tamoxifen citrate and must be eligible for exposure to higher doses
Beschreibung

Tamoxifen Citrate | Exposure to High dose

Datentyp

boolean

Alias
UMLS CUI [1]
C0079589
UMLS CUI [2,1]
C0332157
UMLS CUI [2,2]
C0444956
patient characteristics:
Beschreibung

Client Characteristics

Datentyp

boolean

Alias
UMLS CUI [1]
C0815172
no history of deep venous thrombosis or pulmonary embolism
Beschreibung

Exclusion Criteria | Deep Vein Thrombosis | Pulmonary Embolism

Datentyp

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2]
C0149871
UMLS CUI [3]
C0034065
no history of endometrial carcinoma
Beschreibung

Exclusion | Endometrial Carcinoma

Datentyp

boolean

Alias
UMLS CUI [1]
C2828389
UMLS CUI [2]
C0476089
no known history of vaginal bleeding, endometriosis, endometrial hyperplasia, endometrial hypertrophy, and/or polyps
Beschreibung

Exclusion Criteria | Vaginal Hemorrhage | Endometriosis | Endometrial Hyperplasia | Endometrial hypertrophy | Polyps

Datentyp

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2]
C2979982
UMLS CUI [3]
C0014175
UMLS CUI [4]
C0014173
UMLS CUI [5]
C0858833
UMLS CUI [6]
C0032584
not pregnant or nursing
Beschreibung

Exclusion Criteria | Pregnancy | Breast Feeding

Datentyp

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2]
C0032961
UMLS CUI [3]
C0006147
no contraindication to tamoxifen citrate treatment
Beschreibung

Exclusion | Medical contraindication Tamoxifen Citrate

Datentyp

boolean

Alias
UMLS CUI [1]
C2828389
UMLS CUI [2,1]
C1301624
UMLS CUI [2,2]
C0079589
no known allergy to midazolam or dextromethorphan
Beschreibung

Exclusion Criteria | Midazolam allergy | Hypersensitivity Dextromethorphan

Datentyp

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2]
C0570821
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0011816
prior concurrent therapy:
Beschreibung

Therapeutic procedure

Datentyp

boolean

Alias
UMLS CUI [1]
C0087111
see disease characteristics
Beschreibung

ID.12

Datentyp

boolean

Ähnliche Modelle

Eligibility Breast Cancer NCT00963209

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
Breast Carcinoma
Item
diagnosis of breast cancer
boolean
C0678222 (UMLS CUI [1])
Breast Carcinoma Hormone Responsive | Estrogen receptor positive Percentage Immunohistochemistry | Progesterone receptor positive Percentage Immunohistochemistry
Item
hormone-sensitive breast cancer defined as > 10% estrogen receptor and/or > 10% progesterone receptor positivity by immunohistochemistry
boolean
C0678222 (UMLS CUI [1,1])
C1512498 (UMLS CUI [1,2])
C0279754 (UMLS CUI [2,1])
C0439165 (UMLS CUI [2,2])
C0021044 (UMLS CUI [2,3])
C0279759 (UMLS CUI [3,1])
C0439165 (UMLS CUI [3,2])
C0021044 (UMLS CUI [3,3])
Tamoxifen Citrate | Exposure to High dose
Item
receiving treatment with tamoxifen citrate and must be eligible for exposure to higher doses
boolean
C0079589 (UMLS CUI [1])
C0332157 (UMLS CUI [2,1])
C0444956 (UMLS CUI [2,2])
Client Characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
Exclusion Criteria | Deep Vein Thrombosis | Pulmonary Embolism
Item
no history of deep venous thrombosis or pulmonary embolism
boolean
C0680251 (UMLS CUI [1])
C0149871 (UMLS CUI [2])
C0034065 (UMLS CUI [3])
Exclusion | Endometrial Carcinoma
Item
no history of endometrial carcinoma
boolean
C2828389 (UMLS CUI [1])
C0476089 (UMLS CUI [2])
Exclusion Criteria | Vaginal Hemorrhage | Endometriosis | Endometrial Hyperplasia | Endometrial hypertrophy | Polyps
Item
no known history of vaginal bleeding, endometriosis, endometrial hyperplasia, endometrial hypertrophy, and/or polyps
boolean
C0680251 (UMLS CUI [1])
C2979982 (UMLS CUI [2])
C0014175 (UMLS CUI [3])
C0014173 (UMLS CUI [4])
C0858833 (UMLS CUI [5])
C0032584 (UMLS CUI [6])
Exclusion Criteria | Pregnancy | Breast Feeding
Item
not pregnant or nursing
boolean
C0680251 (UMLS CUI [1])
C0032961 (UMLS CUI [2])
C0006147 (UMLS CUI [3])
Exclusion | Medical contraindication Tamoxifen Citrate
Item
no contraindication to tamoxifen citrate treatment
boolean
C2828389 (UMLS CUI [1])
C1301624 (UMLS CUI [2,1])
C0079589 (UMLS CUI [2,2])
Exclusion Criteria | Midazolam allergy | Hypersensitivity Dextromethorphan
Item
no known allergy to midazolam or dextromethorphan
boolean
C0680251 (UMLS CUI [1])
C0570821 (UMLS CUI [2])
C0020517 (UMLS CUI [3,1])
C0011816 (UMLS CUI [3,2])
Therapeutic procedure
Item
prior concurrent therapy:
boolean
C0087111 (UMLS CUI [1])
ID.12
Item
see disease characteristics
boolean

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video